Johnson & Johnson has new data showing that combining two of its multiple myeloma therapies – Talvey and Tecvayli – has been ...

England is set to become the first health system globally to offer the "Trojan horse" therapy, belantamab mafodotin (Blenrep), developed by GSK, for patients with multiple myeloma, following its ...

Seoul St. Mary's Hospital, which established the first blood hospital in Korea, revealed the results of the treatment of ...

By the time her cancer was caught, six months after her symptoms began and two days after her 46th birthday, Louise Greenbank ...

Paul Silvester, from Sheffield, was diagnosed with Myeloma in July 2023 after his cancer caused broken vertebrae in his spine ...

A world-first blood cancer therapy called belantamab mafodotin (Blenrep) is now available on the NHS in England for multiple ...

The targeted therapy can stop myeloma from progressing by nearly three times as long as existing treatments, studies suggest.

England's National Health Service said Friday it is the first health system in the world to offer a targeted blood cancer ...

Sundar Jagannath, MBBS, highlights long-term follow-up data from the phase 1b/2 CARTITUDE-1 trial, showing durable responses and potential cures with ciltacabtagene autoleucel in patients with ...

England becomes the first country to offer the world’s pioneering 'Trojan horse' blood cancer drug, through NHS, promising ...

GSK’s Blenrep (belantamab mafodotin) has been recommended by the National Institute for Health and Care Excellence (NICE) as ...

New therapy nearly triples disease-free survival time for some patients with bone marrow cancer in world-first recommendation ...